Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Eberhard Karls University of Tübingen

Status: Completed

Conditions: Systemic Candidiasis; Systemic Aspergillosis

Study type: Observational

Funder types: Other

Identifiers

NCT01040156

UCHT-1209

Details and patient eligibility

About

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pediatric patients under the age of 18 years
• Pediatric patients after HSCT treated with caspofungin
• Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion criteria

• Pediatric patients with uncontrolled hematological malignancies
• Pediatric patients with IFI at start of HSCT

Trial design

0 participants in 2 patient groups

LAmb

Cas